IP Library › Granted Patent US 12,551,462
Granted Patent B2
US 12,551,462 · App. 16/980,187 · Granted Feb 17, 2026

Anti-aging composition with rutin, apigenin, epigallocatechin gallate, lipoic acid and the NAD precursor, niacinamide

Inventors: Nichola Jane Conlon (Tyne and Wear, GB); Malcolm Philip Young (Tyne and Wear, GB)
Assignee: NUCHIDO LIMITED
A61K31/352A61K31/05A61K31/385A61K31/706
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,551,462
App. No.
16/980,187
Granted
Feb 17, 2026
Kind
B2
Abstract

There is described a composition comprising an effective amount of a combination of two or more components selected from a NAD precursor; a NAMPT upregulator; a NQO1 upregulator and a NNMT (nicotinamide N-methyltransferase) downregulator.

Claims (3)

1 . A composition consisting of an effective amount of, from 100 mg to 800 mg niacinamide, from 50 mg to 900 mg rutin, from 100 mg to 800 mg alpha lipoic acid, from 50 mg to 900 mg epigallocatechin gallate (EGCG), from 10 mg to 1,000 mg apigenin and optionally one or more carriers or excipients, wherein said carriers or excipients are selected from the group consisting of solvents, solubilizers, stabilizers, tonicity enhancing agents, buffers, preservatives, diluents, lubricating agents, wetting agents, emulsifiers, plasticizers, opacifiers, humectants, disintegrants, absorbents, colourants, flavours and sweeteners.

2 . A composition according to claim 1 consisting of an effective amount of, from 150 mg to 600 mg niacinamide, from 150 mg to 700 mg rutin, from 150 mg to 700 mg alpha lipoic acid, from 50 mg to 600 mg EGCG, from 10 mg to 1,000 mg apigenin and optionally one or more carriers or excipients, wherein said carriers or excipients are selected from the group consisting of solvents, solubilizers, stabilizers, tonicity enhancing agents, buffers, preservatives, diluents, lubricating agents, wetting agents, emulsifiers, plasticizers, opacifiers, humectants, disintegrants, absorbents, colourants, flavours and sweeteners.

3 . A composition according to claim 1 consisting of an effective amount of, from 200 mg to 600 mg niacinamide, from 150 mg to 700 mg rutin, from 150 mg to 700 mg alpha lipoic acid, from 100 mg to 800 mg EGCG, from 10 mg to 1,000 mg apigenin and optionally one or more carriers or excipients, wherein said carriers or excipients are selected from the group consisting of solvents, solubilizers, stabilizers, tonicity enhancing agents, buffers, preservatives, diluents, lubricating agents, wetting agents, emulsifiers, plasticizers, opacifiers, humectants, disintegrants, absorbents, colourants, flavours and sweeteners.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2020
From: CONLON, NICHOLA JANE; YOUNG, MALCOLM PHILIP
To: NUCHIDO LIMITED
Reel/Frame 054409/0832 →
Priority Claims (2)
GB 1804020 · Mar 13, 2018 · national
GB 1820233 · Dec 12, 2018 · national
Continuity (1)
Related Publication 20210015788A1 · Jan 21, 2021
References Cited (21)
US 3671532A · Carraz · 1972 [cited by examiner]
US 5023245A · Kuhrts · 1991 [cited by examiner]
US 8906414B1 · Shytle · 2014 [cited by examiner]
US 10722529B2 · Rappaport · 2020 [cited by examiner]
US 20030138506A1 · Jensen · 2003 [cited by examiner]
US 20070160590A1 · McCleary · 2007 [cited by examiner]
US 20080260934A1 · Bok · 2008 [cited by examiner]
US 20090312355A1 · Bachovchin · 2009 [cited by examiner]
US 20100215768A1 · Pero et al. · 2010 [cited by applicant]
US 20110110913A1 · Grant · 2011 [cited by examiner]
US 20110274680A1 · Mazed · 2011 [cited by examiner]
US 20170143752A1 · Bernstein · 2017 [cited by applicant]
CN 107308160 · 2017 [cited by applicant]
WO 2008011364A1 · 2008 [cited by applicant]
WO 2009108999A1 · 2009 [cited by applicant]
WO 2015070280A1 · 2015 [cited by applicant]
WO 2017062311A1 · 2017 [cited by applicant]
Sun, C., & Zhou, J. (2008). Trichostatin A improves insulin stimulated glucose utilization and insulin signaling transduction through the repression of HDAC2. Biochemical pharmacology, 76(1), 120-127. (Year: 2008). [cited by examiner]
Ryan W. Dellinger et al., “Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a andomized, double-blind, placebo-controlled study”; NPJ Aging and Mechanism… [cited by applicant]
PCT International Search Report and PCT Written Opinion for PCT International Patent Application No. PCT/GB2019/050714; (21 pages). [cited by applicant]
Ashok Jangra et al.; “Amelioration of diabetes-induced neurobehavioral and neurochemical changes by melatonin and nicotinamide: Implication of oxidative stress-PARP pathway”; Pharmacology, Biochemistry, and Behavior; (2… [cited by applicant]